Cadila Pharmaceuticals added Polycap to WHO's 2023 Essential Medicine List, a medication previously sanctioned in 2009 for secondary prevention in patients with multiple risk factors. Polycap helps mitigate hypercholesterolemia and high blood pressure in atherosclerotic cardiovascular disease patients.

According to the company's press release, Polycap reduces cardiovascular risk by nearly 60% in 7000+ patients.

Dr Rajiv Modi, chairman and managing director of Cadila Pharmaceuticals said -

“This validation by WHO is a recognition of our efforts for improving global health. Polycap will help contain the burden of cardiovascular disease and save millions of lives globally.”

Dr. Tedros Adhanom Ghebreyesus Director-General, WHO, said -

“These treatments could have a significant public health impact globally without jeopardizing the budgets of low- and middle-income countries.”